Abstract
Abstract
Objectives
To analyze adverse childhood experiences (ACEs) among mothers of newborns referred to a hospital’s child protection team (CPT) for suspected substance exposure. Researchers hypothesized that a higher prevalence of these mothers have ≥ 4 ACEs than female counterparts in the general population. The study team also explored whether associations existed between type of maternal ACEs and substance use in pregnancy.
Methods
Retrospective review of infant referrals to the CPT in the 3 years after adding an ACEs questionnaire to the consultation process. Bivariate analyses and multivariate logistic regression models examined associations between prenatal substance use and maternal ACEs prevalence, controlling for demographics.
Results
Data from 222 infants (four sets of twins) and 218 mothers were analyzed. Half (50.0%) the infants had withdrawal symptoms. Most (67.0%) women had positive toxicology screens, while 85.0% reported prenatal substance use. Half (50.9%) the mothers reported ≥ 4 ACEs and these individuals had significantly higher odds of cannabinoid use [adjusted odds ratio (aOR), 3.7; 95%CI 2.0, 6.9, p < 0.001) than those with < 4 ACEs. A significant association was found between substance use and ACEs in the household challenges category (p = 0.03), especially parental separation/divorce (p < 0.001).
Conclusions for Practice
As hypothesized, a higher prevalence of mothers referred to the CPT had ≥ 4 ACEs than women in the general population (50.9% vs. 15.2%), and a large proportion had used substances while pregnant. Routine prenatal ACEs screening and universal, nonpunitive toxicology testing of infants and mothers at birth may provide opportunities for intervention while reducing the transgenerational impact of ACEs.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Obstetrics and Gynecology,Pediatrics, Perinatology and Child Health,Epidemiology
Reference46 articles.
1. American College of Obstetricians and Gynecologists. (2023). Substance use disorder in pregnancy: Our position. https://www.acog.org/advocacy/policy-priorities/substance-use-disorder-in-pregnancy
2. Anderson, T. M., Lavista Ferres, J. M., Ren, S. Y., Moon, R. Y., Goldstein, R. D., Ramirez, J. M., et al. (2019). Maternal smoking before and during pregnancy and the risk of sudden unexpected infant death. Pediatrics. https://doi.org/10.1542/peds.2018-3325
3. Austin, A. E., Naumann, R. B., & Simmons, E. (2022). Association of state child abuse policies and mandated reporting policies with prenatal and postpartum care among women who engaged in substance use during pregnancy. JAMA Pediatrics, 176(11), 1123–1130. https://doi.org/10.1001/jamapediatrics.2022.3396
4. Azofeifa, A. M., Mattson, M. E., Schauer, G., McAfee, T., Grant, A., & Lyerla, R. (2016). National estimates of marijuana use and related indicators—National survey on drug use and health, United States, 2002–2014. Morbidity and Mortality Weekly Report Surveillance Summaries, 65(11), 1–28. https://doi.org/10.15585/mmwr.ss6511a1
5. Batty, G. D., Der, G., & Deary, I. J. (2006). Effect of maternal smoking during pregnancy on offspring’s cognitive ability: Empirical evidence for complete confounding in the US national longitudinal survey of youth. Pediatrics, 118(3), 943–950. https://doi.org/10.1542/peds.2006-0168